Shots:

• Fibrocor to receive upfront- option exercise fee- milestones and royalties on sales of the product. Galapagos to receive an exclusive option to in-license up to 4 targets- out of which two reached the lead optimization stage
• Galapagos takes an equity stake in Fibrocor and will get an exclusive global right to commercialize the developed targets and will be responsible for all development activities after lead optimization stage
• The expanded collaboration broadens Galapagos’s fibrotic pipeline addressing the unmet medical needs of patients

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Emwa